Roche says new hemophilia drug cuts bleed rate by 87 percent

ZURICH (Reuters) - Roche's investigational hemophilia drug emicizumab cut the bleed rate by 87 percent in patients who had developed resistance to standard treatment, compared with those who instead got bypassing agents, the Swiss company said on Monday.